Approvals· July 16, 2026 · 17 min read
Lipfendra (enlicitide) coverage: first oral PCSK9 inhibitor approval
By Ran Chen#Cardiovascular#PCSK9#FDA Approval
Topic
PCSK9
PCSK9 inhibitor access, lipid outcomes evidence, prior authorization, payer criteria, and affordability.
Pricing & Access· May 25, 2026 · 9 min read
PCSK9 inhibitor access landscape: Repatha, Praluent, Leqvio, and Lerochol in 2026
By Ran Chen#PCSK9#Cardiovascular#Coverage Access